Introduction
============

Despite continuously improving therapies, gastric cancer (GC) still has the second highest mortality rate of all tumor cases in China, with a 5-year survival rate of \~20% ([@b1-ol-0-0-4160]). The incidence of GC is \~934,000, with 41% of new cases diagnosed in China ([@b2-ol-0-0-4160]). In 2008, GC was ranked second in men and fourth in women in terms of incidence, and the second in men and third in women for mortality in China ([@b3-ol-0-0-4160]). Due to its asymptomatic character and lack of specific symptoms in the early stages, GC is often diagnosed in the later stage of the disease (III or IV) with high rates of lymph node metastasis ([@b4-ol-0-0-4160]). This leads to its poor prognosis. Invasion and metastasis are regulated at multiple molecular levels and by angiogenesis factors ([@b5-ol-0-0-4160]). Considering that GC is, at present, a largely incurable malignant disease, improved understanding of cancer cells is essential for the development of novel detection and therapeutic strategies.

Anterior gradient 2 (AGR2) protein is elevated in numerous types of cancer, including breast ([@b6-ol-0-0-4160],[@b7-ol-0-0-4160]), lung ([@b8-ol-0-0-4160]), ovarian ([@b9-ol-0-0-4160]), esophageal ([@b10-ol-0-0-4160]), prostate ([@b11-ol-0-0-4160]) and pancreatic cancer ([@b12-ol-0-0-4160]), and was reported to be associated the metastatic phenotype and poor prognosis of breast cancer ([@b6-ol-0-0-4160]). However, the association between AGR2 expression, and prognosis and survival in GC remains largely unknown.

Cathepsin D (CTSD) is a common aspartic lysosomal endopeptidase. Its overexpression is positively associated with gastric carcinoma ([@b13-ol-0-0-4160]--[@b15-ol-0-0-4160]), melanoma ([@b16-ol-0-0-4160]), ovarian cancer ([@b17-ol-0-0-4160]) and colorectal cancer ([@b18-ol-0-0-4160]). CTSD levels were reported to be higher in tumors compared with in adjacent noncancerous tissue in colorectal cancer ([@b19-ol-0-0-4160],[@b20-ol-0-0-4160]). Furthermore, CTSD was reported to degrade and remodel the basement membrane and interstitial stroma surrounding primary breast cancer tumors ([@b21-ol-0-0-4160]), and stimulate apoptotic caspases or cooperate with tumor associated pathogenic lysosomal cysteine cathepsins ([@b22-ol-0-0-4160]). In addition, AGR2 was reported to promote *in vitro* and *in vivo* dissemination of cancer cells through posttranscriptional induction of two proteases, cathepsin B and CTSD ([@b12-ol-0-0-4160]).

The present study was conducted to investigate the expression of AGR2, and its association with the progression and prognosis of patients with GC. The potential association between AGR2 and CTSD expression in GC cancer progression was also analyzed. AGR2 expression was detected and positively associated with the CTSD expression level and specific clinicopathological parameters of patients with GC.

Patients and methods
====================

### Patient collection and sample preparation

The procedures of patient collection and sample preparation were described previously ([@b23-ol-0-0-4160],[@b24-ol-0-0-4160]). There were a total of 528 samples (436 cancer samples and 92 adjacent noncancerous tissue samples) collected during gastrectomies performed at the Zhejiang Provincial People\'s Hospital (Hangzhou, China).

### Construction of tissue microarray

Sample preparation was performed as previously described ([@b25-ol-0-0-4160],[@b26-ol-0-0-4160]). Briefly, core tissue biopsies (2 mm in diameter) were obtained/sampled from each individual paraffin-embedded gastric tumor sample (donor blocks) and arranged in recipient paraffin blocks (tissue array blocks) using a trephine, as a previous study indicated that staining results obtained from different intratumoral areas in various tumors correlate well ([@b27-ol-0-0-4160]). Cases in which the tumor occupied \>10% of the core area were selected for further investigation ([@b28-ol-0-0-4160]). Each block contained \>3 internal controls consisting of nonneoplastic gastric mucosa. Sections (4-µm thick) were cut from each tissue array block, deparaffinized and dehydrated.

The project was approved by the Ethics Committee of Zhejiang Provincial People\'s Hospital and written consent was obtained from all participants.

### Immunohistochemistry (IHC)

IHC was performed for detecting AGR2 and CTSD in 528 tissues (with 92 control samples and 436 GC samples) ([@b29-ol-0-0-4160],[@b30-ol-0-0-4160]). The procedures were performed using an EnVision kit (K4011 HRP, Rabbit (DAB+); Dako, Glostrup, Denmark) in accordance with previous studies ([@b23-ol-0-0-4160],[@b24-ol-0-0-4160]). In brief, the slides were baked overnight at 60°C, followed by deparaffinization with xylene and rehydrated in graded alcohol. The sections were submerged into EDTA (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and microwaved for 10 min for antigenic retrieval. Subsequently, 3% hydrogen peroxide (Invitrogen; Thermo Fisher Scientific, Inc.) in methanol was used to quench endogenous peroxidase activity, followed by incubation with 1% bovine serum albumin (Pierce Biotechnology, Inc., Rockford, IL, USA) to block nonspecific binding. Sections were incubated with anti-human rabbit monoclonal anti-AGR2 (cat. no. 2533-1; 1:500) and anti-CTSD antibodies (cat. no. 2487-1; 1:750) (Epitomics, Inc., Burlingame, CA, USA) overnight at 4°C. Normal goat serum (10000C; Invitrogen; Thermo Fisher Scientific, Inc.) was used as a negative control. Subsequent to rinsing with phosphate buffer (pH=7.2) three times, the slides were incubated with the secondary antibody (EnVision kit; Dako) for 20 min at room temperature and stained with diaminobenzidine (Vector Laboratories, Inc., Burlingame, CA, USA). All the slides were counterstained with hematoxylin (Vector Laboratories, Inc.), dehydrated and mounted with a coverslip using a standard medium. The slides were visualized using the Axioskop 40 microscope (Carl Zeiss AG, Oberkochen, Germany Two independent observers, who were blinded to the study design, were employed to review the results and score all of the samples, as previously described ([@b23-ol-0-0-4160]). The staining intensity was scored as 0 (no staining), 1 (weak staining, light yellow), 2 (moderate staining, yellow brown) and 3 (strong staining, brown), and the proportion of stained tumor cells was classified as 0 (≤5% positive cells), 1 (6--25% positive cells), 2 (26--50% positive cells) and 3 (≥51% positive cells). The expression of both proteins was considered low if the product of the staining intensity and proportion of stained tumor cells scores was ≤3 and high if the product was ≥4.

### Statistical analysis

Data analysis was conducted with SPSS software (version 16.0; SPSS, Inc., Chicago, IL, USA). Measurement data were analyzed using the Student\'s t-test, whereas χ^2^ or Fisher\'s exact tests were used to examine the correlation between AGR2 and CTSD expression, and their clinicopathological parameters. Furthermore, Spearman\'s rank correlation tests were used to analyze the association between AGR2 and CTSD expression. Comparisons between survival curves, which were calculated using the Kaplan-Meier method, were performed by univariate survival analysis using the log-rank test. The prognostic value of AGR2 and CTSD expression were assessed by stepwise multivariate analysis using the Cox proportional hazards regression model. In addition, correlation coefficients between protein expression levels and clinicopathological findings were estimated using the Pearson correlation method. Variables that were significant in the univariate analysis were included in the model with backward Cox regression (the Wald method). P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### AGR2 and CTSD expression are significantly higher in GC compared with adjacent noncancerous tissue

AGR2 was detected by IHC in 228/436 (52.3%) cases of GC, with 204 (46.8%) classified as high expression. By contrast, only 29 (31.5%) cases exhibited AGR2 expression in the noncancerous control group, all of which were classified as low expression. The IHC results indicated that AGR2 was predominantly located in the cytoplasm of GC cells ([Fig. 1](#f1-ol-0-0-4160){ref-type="fig"}). Its expression was significantly higher in GC samples compared with control samples (P\<0.05; data not shown). As expected, expression of CTSD was detected in 215/436 (49.3%) GC samples, with 138 (31.7%) exhibiting high expression. Only 27 (29.3%) cases of AGR2 expression were detected in the control group, all of which were low expression. CTSD was predominantly distributed in the cytoplasm in a similar manner to AGR2 ([Fig. 2](#f2-ol-0-0-4160){ref-type="fig"}). Its expression was significantly higher in GC samples compared with the noncancerous control samples (P\<0.05; data not shown).

### High AGR2 expression and CTSD expression are correlated in gastric cancer

High coincidental expression of AGR2 and CTSD in GC samples. Of the 204 patients with high expression of AGR2, 152 (74.5%) exhibited high expression of CTSD. The correlation was statistically significant (r=0.577, P\<0.01).

### AGR2 and CTSD are associated with clinicopathological parameters

The Pearson correlation method was used to determine the association between AGR2 and CTSD expression with clinicopathological parameters of patients with GC. The results indicated that AGR2 was significantly associated with location of the tumor, tumor size, depth of invasion, TNM stage, Lauren\'s classification, vessel invasion, lymphatic metastasis, regional lymph nodes and distant metastasis of tumor (P\<0.05; [Table I](#tI-ol-0-0-4160){ref-type="table"}); however, no significant correlation was identified with gender, age, grade of differentiation and histological type of the tumor (P\>0.05; [Table I](#tI-ol-0-0-4160){ref-type="table"}). Furthermore, GC patients with deep tumor invasion (T3 and T4), high TNM stage (stages III and IV), vessel invasion, lymph node metastasis and distant metastasis exhibited significantly higher expression of AGR2 compared to those with superficial tumor invasion (T1 and T2), low TNM stage (stages I and II), and no vessel invasion, lymph node metastasis or distant metastasis ([Table I](#tI-ol-0-0-4160){ref-type="table"}). The associations between the clinicopathological parameters and CTSD expression were consistent with those of AGR2.

### AGR2 and CTSD expression are associated with prognosis

GC patients with low AGR2 expression had a significantly longer mean survival time (52.9 months) compared with those patients exhibiting high AGR2 expression (32.4 months). In agreement with this result, the 3- and 5-year cumulative survival rates were 90.9 and 57.3% versus 36.9 and 5.7%, respectively. These results indicated that high expression of AGR2 was correlated with significantly poorer prognosis compared with those exhibiting low AGR2 expression (P\<0.05). Furthermore, the results of CTSD were in line with AGR2 regarding to mean survival time and 3- and 5-year cumulative survival rate. In addition, factors significantly associated with survival were assessed using univariate analysis, and it was found that age, tumor size, location, depth of invasion, TNM stage, Lauren\'s classification, vessel invasion, and lymph node and distant metastasis were significantly related to the prognosis while histological type and grade of differentiation were not ([Table II](#tII-ol-0-0-4160){ref-type="table"}). After stratifying by TNM stage, we found that low expression of AGR2 was significantly related longer mean survival time only in stage I, II and III. In particular, there was no significant difference in survival times between low and high expression AGR2 in stage IV ([Fig. 3](#f3-ol-0-0-4160){ref-type="fig"}). Multivariate analysis was employed to further determine the correlation of the clinicopathological parameters identified by univariate analysis with the survival of GC patients. The results of Cox regression model indicated that depth of invasion, vessel invasion, lymph node metastasis, distant metastasis, Lauren\'s classification, and AGR2 expression were independent prognostic factors, whereas age, location and size of tumor, TNM stage and CTSD expression were not ([Table III](#tIII-ol-0-0-4160){ref-type="table"}).

Discussion
==========

As a p52 suppressor inhibitor, AGR2 has been widely investigated in several types of human carcinogenesis ([@b6-ol-0-0-4160]--[@b12-ol-0-0-4160]); however, its exact functions and regulation have been largely unclear. In the present study, microarray tissue samples were initially used to evaluate the protein expression of AGR2 and CTSD in GC patients and its prognostic implications. Increased AGR2 expression in GC tissues was detected compared with adjacent noncancerous tissue. Significant associations were identified between AGR2 and location and size of tumor, TNM stage, depth of invasion, vessel invasion, lymph node and distant metastasis and Lauren\'s classification. Patients in late TNM stages (III and IV), with deep invasion (T3 and T4), presence of vessel invasion, and lymph node and distant metastasis exhibited the highest level of AGR2. These findings indicate that upregulation of AGR2 was involved in the progression of GC.

AGR2 is known as a stimulator of cancer cell proliferation, invasion and survival, chemotherapy resistance, metastasis and tumor growth ([@b6-ol-0-0-4160],[@b7-ol-0-0-4160],[@b9-ol-0-0-4160],[@b11-ol-0-0-4160],[@b12-ol-0-0-4160]). Secretion of AGR2 was been reported to correlate with metastasis and poor prognosis in breast cancer, and considered as a biomarker in prostate cancer ([@b31-ol-0-0-4160]--[@b33-ol-0-0-4160]). AGR2 upregulation was also detected in pancreatic carcinoma tissues ([@b34-ol-0-0-4160],[@b35-ol-0-0-4160]). In GC tissues, higher expression in GC cells has previously been reported to be evident in the cytoplasm compared with non-tumor cells ([@b36-ol-0-0-4160]). Notably, AGR2 can be used as a suitable candidate gene for the detection of circulating tumor cells, a novel resource to identification of molecular markers, in patients with gastrointestinal cancer ([@b37-ol-0-0-4160],[@b38-ol-0-0-4160]).

To the best of our knowledge, prognostic factors of GC includes invasion depth, TNM stage, and lymph node and distant metastasis ([@b39-ol-0-0-4160]). In the present study, AGR2 was identified as a novel independent prognostic factor that was significantly associated with poor prognosis in patients with GC. The current study also revealed that low expression of AGR2 was significantly associated with longer mean survival time in TNM stages I, II and III.

AGR2 shares structural characteristics with the protein disulfide isomerase (PDI) family. The PDI family has important roles on the cell surface, as the majority of surface proteins contain disulfide bonds in which they can modulate the activity of membrane receptors (and thus activate and regulate signaling pathways), adhesion molecules integrins, or even proteases, such as ADAM metallopeptidase domain 17 ([@b40-ol-0-0-4160]--[@b45-ol-0-0-4160]).

The current findings also indicated significant positive correlation between the expression of AGR2 and CTSD in GC tissues. In agreement with AGR2 expression, CTSD, which is known as an aspartic lysosomal endopeptidase, was significantly correlated with location and size of tumor, depth of invasion, vessel invasion, TNM stage, distant metastasis, lymph node metastasis, regional lymph node and Lauren\'s classification in the present study. Overexpression of CTSD has previously been reported in several types of human cancer, including GC ([@b13-ol-0-0-4160]--[@b15-ol-0-0-4160]), melanoma ([@b16-ol-0-0-4160]) and ovarian cancer ([@b17-ol-0-0-4160]). It may have a direct role in promoting tumor growth by basement membrane and interstitial stroma degradation and remodeling ([@b21-ol-0-0-4160]). Furthermore, CTSD is able to stimulate other enzymes and cooperate with certain cathepsins in the proteolysis process ([@b22-ol-0-0-4160]). CTSD has been reported to be upregulated by AGR2 in pancreatic cancer ([@b12-ol-0-0-4160]). The underlined mechanism may be the direct effect of AGR2 PDI activity in the ER during the processing of pro-cathepsins, as previously reported for the production of MUC2 in enterocytes ([@b46-ol-0-0-4160]).

Taken together, the present study indicated that upregulation of AGR2 may contribute to the expression of CTSD as the direct result of AGR2 PDI activity in the ER. The cross-talk of AGR2 and CTSD is possibly involved in the carcinogenesis, development and progression of GC.

The present study still has a number of limitations. First, the subjective nature of the scoring method could not be avoided and further investigation is recommended to evaluate the reproducibility of IHC scores system. Furthermore, standardization and quality control for IHC procedures is required prior to its clinical application ([@b47-ol-0-0-4160]).
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![Immunohistochemical staining for anterior gradient protein 2 in gastric cancer and non-cancerous adjacent (EnVision method). (Aa-Ac) Strong staining in moderately differentiated papillary adenocarcinoma; (Ba-Bc) strong staining in poorly differentiated adenocarcinoma; (Ca-Cc) strong staining in moderately differentiated tubular adenocarcinoma; (Da-Dc) strong staining in mucinous adenocarcinoma; and (Ea-Ec) no staining in non-cancerous gastric mucosa. Original magnification: ×40 (Aa-Ea), ×100 (Ab-Eb), and ×400 (Ac-Ec).](ol-11-03-2075-g00){#f1-ol-0-0-4160}

![Immunohistochemical staining for cathepsin D in gastric cancer and non-cancerous adjacent tissue (EnVision method). (Aa-Ac) Strong staining in poorly differentiated adenocarcinoma; (Ba-Bc) moderate staining in papillary adenocarcinoma; (Ca-Cc) strong staining in moderately differentiated tubular adenocarcinoma; (Da-Dc) strong staining in poorly differentiated tubular adenocarcinoma; (Ea-Ec) and non-cancerous gastric mucosa, poor staining in stromal cells, and no staining in columnar epithelium. Original magnifications: ×40 (Aa-Ea), ×100 (Ab-Eb) and ×400 (Ac-Ec).](ol-11-03-2075-g01){#f2-ol-0-0-4160}

![Kaplan-Meier survival curves of gastric cancer patients with high and low AGR2 expression, stratified by TNM stage of the tumor (log-rank test). (A) Survival in stage I (z=40.266, P=0.000); (B) stage II (z=10.108, P=0.001); (C) stage III (z=10.396, P=0.001); and (D) stage IV (z=1.774, P=0.183) gastric cancer with low versus high AGR2 expression. Cum, cumulative; AGR2, anterior gradient protein 2.](ol-11-03-2075-g02){#f3-ol-0-0-4160}

###### 

Association of AGR2 and CTSD expression with clinicopathological parameters of patients with gastric cancer.

                                     High AGR2 expression   High CTSD expression                                       
  -------------------------- ------- ---------------------- ---------------------- --------- --------------- --------- ---------
  Gender                                                    0.556                    0.456                   0.148       0.700
    Male                     311     142 (45.7)                                                138 (44.4)              
    Female                   125       62 (49.6)                                                 58 (46.4)             
  Age range, years                                          3.632                    0.057                   3.401       0.065
    ≤60                      237     101 (42.6)                                                97 (40.9)               
    \>60                     199     103 (51.8)                                                99 (49.7)               
  Location of tumor                                         6.906                    0.032                   9.798       0.007
    Cardia                     55      34 (61.8)                                               34 (61.8)               
    Body                     163       78 (47.9)                                               77 (47.2)               
    Antrum                   218       92 (42.2)                                               85 (39.0)               
  Tumor size, cm                                            23.336                 \<0.001                   22.176    \<0.001
    \<5                      256       95 (37.1)                                               91 (35.5)               
    ≥5                       180     109 (60.0)                                              105 (58.3)                
  Depth of invasion                                         70.250                 \<0.001                   71.524    \<0.001
    T1                         57      4 (7.0)                                                 4 (7.0)                 
    T2                       109       36 (33.0)                                               33 (30.3)               
    T3                       244     143 (58.6)                                              137 (56.1)                
    T4                         26      21 (80.8)                                               22 (84.6)               
  TNM stage                                                 168.125                \<0.001                   132.672   \<0.001
    I                          90      5 (5.6)                                                 8 (8.9)                 
    II                       104       21 (20.2)                                               22 (21.2)               
    III                      173     118 (68.2)                                              110 (63.6)                
    IV                         69      60 (87.0)                                               56 (81.2)               
  Vessel invasion                                           93.143                 \<0.001                   61.702    \<0.001
    Negative                 183       36 (19.7)                                               42 (23.0)               
    Positive                 253     168 (66.4)                                              154 (60.9)                
  Lymphatic metastasis                                      108.752                \<0.001                   89.160    \<0.001
    Negative                 166       25 (15.1)                                               27 (16.3)               
    Positive                 270     179 (66.3)                                              169 (62.6)                
  Regional lymph nodes                                      126.361                \<0.001                   100.981   \<0.001
    PN0                      166       25 (15.1)                                               27 (16.3)               
    PN1                      136       74 (54.4)                                               73 (53.7)               
    PN2                        99      74 (74.7)                                               67 (67.7)               
    PN3                        35      31 (88.6)                                               29 (82.9)               
  Distant metastasis                                        38.614                 \<0.001                   39.265    \<0.001
    Negative                 375     153 (40.8)                                              146 (38.9)                
    Positive                   61      51 (83.6)                                               50 (82.0)               
  Lauren\'s classification                                  153.612                \<0.001                   113.254   \<0.001
    Intestinal               166       40 (17.9)                                               45 (27.1)               
    Diffuse                  270     164 (77.0)                                              151 (55.9)                
  Grade of differentiation                                    5.285                  0.152                     4.782     0.188
    Well                       13        3 (23.1)                                                3 (23.1)              
    Moderately               128       58 (45.3)                                               62 (48.4)               
    Poorly                   293     143 (48.8)                                              131 (44.7)                
    Not                          2     0 (0.0)                                                 0 (0.0)                 
  Histological type                                           3.671                  0.299                   5.059       0.168
    Papillary                  16        9 (56.2)                                                9 (56.2)              
    Tubular                  326     148 (45.4)                                              143 (43.9)                
    Mucinous                   29      18 (62.1)                                               18 (62.1)               
    Signet-ring cell           65      29 (44.6)                                               26 (40.0)               

Calculated using Student\'s t-test, χ^2^ test or Fisher\'s exact test. AGR2, anterior gradient protein 2; CTSD, cathepsin D.

###### 

Univariate analysis of the correlation between clinicopathological parameters and survival of patients with gastric cancer.

                             Cumulative survival rate, %                                        
  -------------------------- ----------------------------- ----- ------- --------- --------- -- --
  Age range, years                                                       14.745    \<0.001      
    ≤60                      74                            44    45.85                          
    \>60                     59                            29    39.63                          
  Location of tumor                                                      7.849       0.020      
    Cardia                   55                            24    37.76                          
    Body                     67                            39    43.22                          
    Antrum                   71                            39    44.13                          
  Tumor size, cm                                                         49.579    \<0.001      
    \<5                      78                            49    47.50                          
    ≥5                       52                            21    36.63                          
  Histological type                                                      0.934       0.817      
    Papillary                69                            24    41.92                          
    Tubular                  67                            39    43.26                          
    Mucinous                 79                            29    44.35                          
    Gignet-ring cell         63                            38    41.54                          
  Grade of differentiation                                               0.617       0.432      
    Well and moderately      73                            36    44.12                          
    Poorly and not           64                            38    42.45                          
  TNM stage                                                              370.398   \<0.001      
    I                        96                            94    58.09                          
    II                       87                            76    52.97                          
    III                      61                              7   37.70                          
    IV                       16                              1   23.26                          
  Depth of invasion                                                      135.118   \<0.001      
    T1                       93                            91    57.18                          
    T2                       82                            62    50.01                          
    T3                       58                            18    38.38                          
    T4                       35                              8   26.85                          
  Lymph node metastasis                                                  176.051   \<0.001      
    Negative                 88                            82    54.23                          
    Positive                 54                            12    36.30                          
  Distant metastasis                                                     141.372   \<0.001      
    Negative                 75                            43    46.23                          
    Positive                 29                              3   23.18                          
  Vessel invasion                                                        127.41    \<0.001      
    Negative                 90                            70    52.56                          
    Positive                 51                            16    36.26                          
  Lauren\'s classification                                               239.586   \<0.001      
    Intestinal               93                            66    54.12                          
    Diffuse                  40                              9   31.56                          
  AGR2 expression                                                        179.188   \<0.001      
    Low                      91                            57    52.85                          
    High                     37                              6   32.40                          
  CTSD expression                                                        113.445   \<0.001      
    Low                      87                            51    51.12                          
    High                     40                            12    33.70                          

Calculated using the log-rank test. AGR2, anterior gradient protein 2; CTSD, cathepsin D.

###### 

Multivariate analysis of the correlation between clinicopathological parameters and survival time of patients with gastric cancer.

  Covariate                                           Coefficient   Standard error   HR      95% CI         P-value
  --------------------------------------------------- ------------- ---------------- ------- -------------- ---------
  Age range (\>60 vs. ≤60)                            −0.277        0.148            0.758   0.567--1.014   0.062
  Tumor location (cardia vs. others)                    0.046       0.204            1.047   0.702--1.563   0.821
  Tumor size (≥5 vs. \<5 cm)                          −0.265        0.151            0.768   0.571--1.032   0.08
  Lauren\'s classification (diffuse vs. intestinal)   −0.649        0.194            0.523   0.357--0.765   0.001
  Lymph node metastasis (positive vs. negative)       −0.669        0.328            0.512   0.269--0.975   0.042
  Vessel invasion (positive vs. negative)             −0.614        0.205            0.541   0.362--0.809   0.003
  Distant metastasis (positive vs. negative)          −0.503        0.248            0.605   0.372--0.983   0.042
  TNM stage (stages III and IV vs. I and II)          0.263         0.375            1.300   0.624--2.711   0.483
  Depth of invasion (T3, T4 vs. T1, T2)               −0.724        0.268            0.485   0.287--0.819   0.007
  AGR2 expression (high vs. low)                      −0.805        0.189            0.447   0.309--0.647   \<0.001
  CTSD expression (high vs. low)                      −0.215        0.168            0.806   0.580--1.121   0.201

HR, hazard ratio; CI, confidence interval; AGR2, anterior gradient protein 2; CTSD, cathepsin D.
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